FDA Approves NINTEDANIB — Dr. Reddy's Laboratories Inc.

# FDA Approves Dr. Reddy's Laboratories' Generic Nintedanib Dr. Reddy's Laboratories Inc. received FDA approval for its generic nintedanib esylate oral formulation (ANDA219283), marking the company's entry into the competitive market for this pulmonary fibrosis and lung cancer treatment. The approval is expected to increase price competition and improve patient access to nintedanib, a key therapeutic option currently dominated by brand-name originator Ofev.